Factors affecting prescribing of the newer antidepressants

被引:0
|
作者
Garrison, GD [1 ]
Levin, GM [1 ]
机构
[1] Union Univ, Albany Coll Pharm, Albany, NY 12208 USA
关键词
antidepressant; survey; prescribing;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: TO survey various prescriber types and specialties to determine whether differences exist in prescribing patterns for the newer antidepressants. DESIGN, SETTING, AND PARTICIPANTS: A survey about prescribing of the newer antidepressants was mailed to 1500 New York state licensed prescribers who were randomly selected from membership rosters. Nurse practitioners; physician assistants and physicians in family medicine, primary care, general practice, and internal medicine; and psychiatrists were included. MAIN OUTCOME MEASURES: Prescriber responses regarding factors involved with choosing among the newer antidepressants. RESULTS: A total of 508 surveys (36%) were returned, of which 398 (29%) were acceptable for analysis. In choosing among the newer antidepressants, most prescribers ranked patient diagnosis and past success asa high priority, and free drug samples and drug-representative detailing as a law priority. The majority of each prescriber type preferred fluoxetine for major depression and depression associated with fatigue; paroxetine for concomitant anxiety and depression, as well as for panic disorder; and sertraline for geriatric patients and patients with suicidal ideation. Differences existed between the prescriber groups when asked whether prescribing habits for the newer antidepressants were based on familiarity with a particular agent (p = 0.0009) and on labeled indications (p = 0.002). CONCLUSIONS: This is the first study to demonstrate prescribing preferences for the newer antidepressants among different prescriber groups. Additional studies are needed to determine predictors of patient response to newer antidepressants and clinical guidelines for their use.
引用
收藏
页码:10 / 14
页数:5
相关论文
共 50 条
  • [41] Cardiovascular side effects of newer antidepressants
    Fernandez, Antony
    Bang, Suji E.
    Srivathsan, Komandur
    Vieweg, W. Victor R.
    [J]. ANATOLIAN JOURNAL OF CARDIOLOGY, 2007, 7 (03): : 305 - 309
  • [42] The use of newer antidepressants for panic disorder
    Gorman, JM
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 1997, 58 : 54 - 59
  • [43] Cost-effectiveness of newer antidepressants
    Woods, SW
    Baker, CB
    [J]. CURRENT OPINION IN PSYCHIATRY, 1997, 10 (02) : 95 - 101
  • [44] Burden of sexual dsyfunction with newer antidepressants
    Clayton, AH
    McGarvey, EL
    Keller, A
    Pinkerton, R
    [J]. MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2003, 10 (06): : 583 - 583
  • [45] The safety of newer antidepressants in pregnancy and breastfeeding
    Gentile, S
    [J]. DRUG SAFETY, 2005, 28 (02) : 137 - 152
  • [46] PHARMACOKINETIC OPTIMIZATION OF THERAPY WITH NEWER ANTIDEPRESSANTS
    GOODNICK, PJ
    [J]. CLINICAL PHARMACOKINETICS, 1994, 27 (04) : 307 - 330
  • [47] SPEED OF ONSET OF ACTION OF THE NEWER ANTIDEPRESSANTS
    LYDIARD, RB
    POTTASH, ALC
    GOLD, MS
    [J]. PSYCHOPHARMACOLOGY BULLETIN, 1984, 20 (02) : 258 - 271
  • [48] Are newer antidepressants really "better tolerated"?
    Robinson, MJ
    [J]. CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2001, 46 (03): : 286 - 287
  • [50] Cardiovascular adverse effects of newer antidepressants
    Mago, Rajnish
    Tripathi, Neeta
    Andrade, Chittaranjan
    [J]. EXPERT REVIEW OF NEUROTHERAPEUTICS, 2014, 14 (05) : 539 - 551